The phase III KEYNOTE-604 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival in the first-line treatment of patients with extensive stage small cell lung cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
